Table 2. The HRs of studies about overall survival.

Study	n	Cancer type	ICIs treatment line	TMB cut-off value	HR (95% CI)
Aaron M	151	Melanoma, NSCLC and other	N/A	Top 25%	0.33 (0.19–0.58)
Robert M	117	Advanced glioma			1.25 (0.91–1.72)
	126	Advanced esophagogastric cancer	N/A	N/A	1.28 (0.91–1.79)
	151	Advanced renal cell carcinoma			0.41 (0.29–0.58)
	138	Advanced head and neck cancer			1.20 (0.88–1.64)
Bixia Tang	36	Melanoma or urothelial cancer or renal cell cancer	3+	6 Muts/MB	0.36 (0.17–0.75)
Douglas B. Johnson	41	Metastatic melanoma	N/A	23.1 Muts/MB	0.09 (0.02–0.32)
Marcin Kowanetz	102	Advanced NSCLC	1	13.5 Muts/MB	0.70 (0.49–1.00)
	371	Advanced NSCLC	2+	13.5 Muts/MB	0.7 (0.49–1.00)
Di Huang	34	Advanced NSCLC	1L/2L/3L	10 Muts/MB	0.37 (0.17–0.81)
Romualdo Barroso-Sousa	62	Metastatic triple-negative breast cancer	N/A	10 Muts/MB	0.54 (0.23–1.26)
Yuan Li	215	Bladder		24.5 Muts/MB	0.43 (0.20–0.95)
	44	Breast		6.8 Muts/MB	0.68 (0.20–2.30)
	110	Colorectal		68.8 Muts/MB	0.82 (0.32–2.09)
	126	Esophagogastric	N/A	13.9 Muts/MB	0.46 (0.16–1.31)
	117	Glioma		8.2 Muts/MB	0.83 (0.36–1.94)
	139	Head and neck cancer		12.2 Muts/MB	0.60 (0.24–1.12)
	321	Melanoma		20.2 Muts/MB	0.52 (0.24–1.12)
	350	NSCLC		45.7 Muts/MB	0.32 (0.17–0.59)
	151	Renal cell carcinoma		7.8 Muts/MB	0.70 (0.27–1.76)
Wenfeng Fang	78	Advanced NSCLC	N/A	10 Muts/MB	0.45 (0.27–0.76)
F. Wang	58	Advanced gastric cancer (chemo refractory)	2+	12 Muts/MB	0.48 (0.24–0.96)
Ilaria Alborelli	76	NSCLC	1+	9 Muts/MB	0.51 (0.29–0.90)
Aaron M. Goodman	77	HSCC, NSCLC, cutaneous squamous cell carcinoma	N/A	10 Muts/MB	0.42 (0.21–0.82)